Basel Medical restores Nasdaq filing compliance

Basel Medical Group Ltd reports that Nasdaq has confirmed the company is now in full compliance with the exchange’s periodic filing requirement under Listing Rule 5250(c)(1).

Rhea-AI Filing Summary

Basel Medical Group Ltd reports that Nasdaq has confirmed the company is now in full compliance with the exchange’s periodic filing requirement under Listing Rule 5250(c)(1). This follows Basel Medical’s amended Form 20-F for fiscal year 2025, filed on March 13, 2026, and means the prior filing-related deficiency has been resolved.

The company continues operating as a Singapore-based medical services group focused on orthopedic, neurosurgical and general healthcare, serving corporate and individual patients across multiple clinic locations in Singapore.

Positive

• Nasdaq filing deficiency resolved: Nasdaq confirmed Basel Medical is now compliant with Listing Rule 5250(c)(1) after its amended 2025 Form 20-F, removing a prior periodic filing deficiency that could have escalated into listing risk if left unresolved.

Negative

• None.

Insights

Regulatory & Listing Compliance Analyst

Basel Medical has restored full Nasdaq filing compliance, removing a prior deficiency.

Basel Medical Group confirms that Nasdaq now considers it compliant with the periodic filing requirement under Listing Rule 5250(c)(1). This change follows the company’s amended Form 20-F for fiscal year 2025, which Nasdaq reviewed before determining the deficiency was cured.

Resolving a filing deficiency is important because persistent non-compliance can ultimately jeopardize an exchange listing. With the issue closed, attention can return to Basel Medical’s core operations in Singapore-based orthopedic, trauma, neurosurgical and general medical services rather than listing risk tied to reporting delays.

Future results and SEC reports will show whether the company maintains timely filing practices. Consistent compliance will be key to avoiding renewed Nasdaq scrutiny related to reporting obligations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Basel Medical Group Ltd (BMGL) announce in this 6-K filing?

Basel Medical announced that Nasdaq has determined the company now complies with its periodic filing requirement under Listing Rule 5250(c)(1). This decision followed the company’s amended Form 20-F for fiscal year 2025 filed on March 13, 2026, which resolved a prior deficiency.

What Nasdaq rule is Basel Medical Group Ltd now compliant with?

Basel Medical is now compliant with Nasdaq Listing Rule 5250(c)(1), which covers periodic filing requirements. Nasdaq staff notified the company after reviewing its amended Form 20-F for fiscal year 2025, confirming the earlier filing-related deficiency has been fully resolved and closed.

How did Basel Medical Group Ltd resolve its prior Nasdaq filing deficiency?

The company resolved its prior deficiency by filing an amended annual report on Form 20-F for fiscal year 2025 with the SEC on March 13, 2026. After reviewing that amended filing, Nasdaq staff determined Basel Medical had satisfied the periodic filing requirement under Listing Rule 5250(c)(1).

Does this 6-K indicate any ongoing Nasdaq compliance issues for BMGL?

The disclosure states that Nasdaq has determined Basel Medical has complied with the periodic filing requirement and that the prior deficiency is now resolved. Based on this announcement, the specific issue under Listing Rule 5250(c)(1) has been closed, with no ongoing deficiency cited here.

What type of business does Basel Medical Group Ltd operate?

Basel Medical operates a Singapore-based healthcare group providing orthopedic and trauma services, sports medicine, neurosurgical treatments, executive health screening, occupational medicine, rehabilitation, mental and women’s health, and general medical practice through multiple clinics across various locations in Singapore.

Where are Basel Medical Group Ltd’s clinics located in Singapore?

The company’s operations are based in Singapore, with clinics located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre, supporting both corporate clients and individual patients across a wide range of medical services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/24/2026 - 06:30 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-42527

Basel Medical Group Ltd

6 Napier Road,

Unit #02-10/11 Gleneagles Medical Centre

Singapore 258499

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Exhibit Index

Exhibit No.		Description
99.1		Press Release – Compliance With Nasdaq Periodic Filing Requirement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Basel Medical Group Ltd
	By:	/s/ Darren Yen Feng Chhoa
	Name:	Dr. Darren Yen Feng Chhoa
	Title:	Chief Executive Officer
Date: March 24, 2026

Exhibit 99.1

Compliance With Nasdaq Periodic Filing Requirement

Singapore, March 24, 2026 (GLOBE NEWSWIRE) — Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company’s amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.

About Basel Medical Group Ltd

Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, particularly those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.

Media Contact:

Basel Medical Group Ltd

+65 6291 9188

contact@baselmedical.com

www.baselmedical.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 9.8 KB